Who are WF10's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): histamine dihydrochloride and IL-2, Thymosin Alpha 1, FTY720, Interferon-Alpha, Ixazomib plus low-dose lenalidomide, Thymosin Alpha.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/wf10.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

WF10 — Competitive Intelligence Brief

WF10 (WF10) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator. Area: Immunology.

phase 3 Immunomodulator Immunology Small molecule Live · refreshed every 30 min

Target snapshot

WF10 (WF10) — Oxo Chemie GmbH. WF10 is a stable, diluted solution of dihydroxyethyl disulfide that acts as an immunomodulator and antioxidant to enhance immune function and reduce inflammatory responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
WF10 TARGET	WF10	Oxo Chemie GmbH	phase 3	Immunomodulator
histamine dihydrochloride and IL-2	histamine dihydrochloride and IL-2	Cytovia, Inc.	marketed	Immunomodulator combination	Histamine receptors (H1, H2, H3, H4) and IL-2 receptor
Thymosin Alpha 1	Thymosin Alpha 1	Xuanwu Hospital, Beijing	marketed	Immunomodulator	T-cell maturation pathway / thymic differentiation
FTY720	FTY720	Novartis Pharmaceuticals	marketed	Sphingosine-1-phosphate receptor modulator; Immunomodulator	Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)
Interferon-Alpha	Interferon-Alpha	University of Birmingham	marketed	Cytokine; Immunomodulator	Interferon-alpha receptor (IFNAR)
Ixazomib plus low-dose lenalidomide	Ixazomib plus low-dose lenalidomide	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Proteasome inhibitor and immunomodulatory agent	Proteasome and cereblon
Thymosin Alpha	Thymosin Alpha	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Immunomodulator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator class)

Actavis Mid-Atlantic LLC · 1 drug in this class
Active Biotech AB · 1 drug in this class
Air Force Military Medical University, China · 1 drug in this class
Astellas Pharma Inc · 1 drug in this class
Bayer · 1 drug in this class
Beijing Children's Hospital · 1 drug in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri · 1 drug in this class
Chang Gung Memorial Hospital · 1 drug in this class
ALK-Abelló A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). WF10 — Competitive Intelligence Brief. https://druglandscape.com/ci/wf10. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab